Wednesday, 16 Oct 2019

You are here

Ominous Outcomes for Lupus Nephritis

Hanly and coworkers have reported the results of a large lupus cohort study involving 1827 patients. SLE patients were enrolled early in their disease (0.5 years) and were followed for a mean of 4.6 years.

Lupus nephritis (LN) was found in 38% patients, with 81% presenting with LN at enrolment and 19% during follow-up. LN was more likely in patients who were younger, male and ethnic (African, Asian or Hispanic).

For all lupus patients the overall 10-year incidence of ESRD was 4.3%, but in those with nephritis was ESRD occurred in 10.1%. Nephritis patients had a 3 fold higher risk of death (HR = 2.98, 95% CI: 1.48, 5.99.

Despite current standard of care, nephritis was associated with ESRD and death, and renal insufficiency was linked to lower health-related quality of life.

Disclosures: 
The author has no conflicts of interest to disclose related to this subject

Add new comment

More Like This

Warfarin Superior to Xarelto in Antiphospholipid Syndrome

A 3 year, multicenter, European, study shows that rivaroxaban was inferior to warfarin in preventing thrombosis in patients with antiphospholipid syndrome (APS) according to the Annals of Internal Medicine. Thus despite the inconvenience of warfarin, it remains the best option for patients with APS.

Declining Trends in Antineutrophil Cytoplasmic Autoantibody–Associated Vasculitis Mortality in the USA

Annals of Internal Medicine reports that age-adjusted mortality rates for antineutrophil cytoplasmic autoantibody–associated vasculitides (AAV) have improved over time - with a decline of nearly 2 percent per year in the United States from 1999 to 2017. Nevertheless, long-term outcomes continue to lag behind mortality rates of the general population.

Serum Interferon Predicts Lupus Flares

Elevated serum levels of interferon-α among patients whose systemic lupus erythematosus (SLE) was in remission helped predict future disease flares, European researchers found.

Among 254 SLE patients who were in remission, 26% had abnormally high serum levels of interferon-α at baseline, according to Alexis Mathian, MD, of Pitié-Salpêtrière Hospital in Paris, and colleagues.

ILD Patients At Risk for Autoimmune Disease

Patients diagnosed with interstitial pneumonia with autoimmune features (IPAF) are at an increased risk of developing a systemic autoimmune rheumatic disease (ARD).

A retrospective study of interstitial lung disease (ILD) patients from the Columbia University Irving Medical Center (2009 to 2017) looked for those who did or did not meet IPAF criteria.

MMWR: Increased Opioid Use in Lupus

Opioids are generally not indicated for pain in systemic lupus erythematosus (SLE) and other rheumatic diseases because of limited efficacy and risks for preference and adverse health effects.